Turner N - Search Results

1

Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?

Turner N, Pestrin M, Galardi F, De Luca F, Malorni L, Di Leo A. Turner N, et al. Cancers (Basel). 2014 Mar 25;6(2):684-707. doi: 10.3390/cancers6020684. Cancers (Basel). 2014. PMID: 24670368 Free PMC article.

2

Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients.

Pestrin M, Salvianti F, Galardi F, De Luca F, Turner N, Malorni L, Pazzagli M, Di Leo A, Pinzani P. Pestrin M, et al. Among authors: turner n. Mol Oncol. 2015 Apr;9(4):749-57. doi: 10.1016/j.molonc.2014.12.001. Epub 2014 Dec 9. Mol Oncol. 2015. PMID: 25539732 Free PMC article.

3

HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact.

Turner NH, Di Leo A. Turner NH, et al. Cancer Treat Rev. 2013 Dec;39(8):947-57. doi: 10.1016/j.ctrv.2013.05.003. Epub 2013 Jun 10. Cancer Treat Rev. 2013. PMID: 23764178 Review.

4

The continued evidence from overviews: what is the clinical utility?

Turner N, Biganzoli L, Malorni L, Migliaccio I, Moretti E, Pestrin M, Sanna G, Siclari O, Di Leo A. Turner N, et al. Breast. 2013 Aug;22 Suppl 2:S8-11. doi: 10.1016/j.breast.2013.07.002. Breast. 2013. PMID: 24074798 Free article. Review.

5

Continued value of adjuvant anthracyclines as treatment for early breast cancer.

Turner N, Biganzoli L, Di Leo A. Turner N, et al. Lancet Oncol. 2015 Jul;16(7):e362-9. doi: 10.1016/S1470-2045(15)00079-0. Lancet Oncol. 2015. PMID: 26149888 Review.

6

Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain.

Turner NH, Partridge A, Sanna G, Di Leo A, Biganzoli L. Turner NH, et al. Ann Oncol. 2013 Sep;24(9):2224-35. doi: 10.1093/annonc/mdt196. Epub 2013 May 24. Ann Oncol. 2013. PMID: 23709175 Free article. Review.

7

Adjuvant chemotherapy: which patient? What regimen?

Turner N, Biganzoli L, Malorni L, Migliaccio I, Moretti E, Pestrin M, Sanna G, Siclari O, Di Leo A. Turner N, et al. Am Soc Clin Oncol Educ Book. 2013:3-8. doi: 10.14694/EdBook_AM.2013.33.3. Am Soc Clin Oncol Educ Book. 2013. PMID: 23714442 Free article.

8

A multifactorial 'Consensus Signature' by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer.

Turner N, Forcato M, Nuzzo S, Malorni L, Bicciato S, Di Leo A. Turner N, et al. NPJ Breast Cancer. 2015 Jun 2;1:15003. doi: 10.1038/npjbcancer.2015.3. eCollection 2015. NPJ Breast Cancer. 2015. PMID: 28721363 Free PMC article.

9

Targeting triple negative breast cancer: is p53 the answer?

Turner N, Moretti E, Siclari O, Migliaccio I, Santarpia L, D'Incalci M, Piccolo S, Veronesi A, Zambelli A, Del Sal G, Di Leo A. Turner N, et al. Cancer Treat Rev. 2013 Aug;39(5):541-50. doi: 10.1016/j.ctrv.2012.12.001. Epub 2013 Jan 12. Cancer Treat Rev. 2013. PMID: 23321033 Review.

10

Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study.

Tenori L, Oakman C, Morris PG, Gralka E, Turner N, Cappadona S, Fornier M, Hudis C, Norton L, Luchinat C, Di Leo A. Tenori L, et al. Among authors: turner n. Mol Oncol. 2015 Jan;9(1):128-39. doi: 10.1016/j.molonc.2014.07.012. Epub 2014 Aug 10. Mol Oncol. 2015. PMID: 25151299 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,881 results

Search Page